Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Sqeeze-out 25.09.2008 The resolution passed by the general meeting on January 17, 2007, on the transfer of the shares held by the remaining shareholders (minority shareholders) of Bayer ...
Tip announcement for financial statements transmitted by euro adhoc. The issuer is responsible for the content of this announcement. The financial statement is available: in the internet at: http://www.schering.de/scripts/en/40_ir/2007/fin_rep/070808_q12.php?n=ird&c1=reports_financial in the internet on: ...
Intermediate report of the management transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 09.05.2007 Interim Announcement by Bayer Schering Pharma AG, May 9, 2007 Bayer Schering Pharma AG gets off to a dynamic start in 2007 On account of the integration of Bayer Schering Pharma AG into the Bayer Group and the associated changes in terms of the legal corporate structure, ...
Tip announcement for financial statements transmitted by euro adhoc. The issuer is responsible for the content of this announcement. The financial statement is available: in the internet at: http://www.schering.de/scripts/en/40_ir/2007/fin_rep/070509_q1.php in the internet on: 09.05.2007 end of ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 05.12.2006 Bayer Schering GmbH, Leverkusen (formerly Dritte BV GmbH) today informed the Management Board of Schering AG that the cash compensation for the requested transfer of the shares of ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 31.07.2006 Schering AG, Germany is voluntarily recalling its X-ray contrast agent Ultravist Injection 370 mgI/mL (iopromide injection) due to the potential that particulate matter in conjunction ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 26.07.2006 In connection with the takeover of Schering AG, Berlin, Germany, by the Bayer Group, a domination and profit and loss transfer agreement between Dritte BV GmbH as the controlling ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 23.03.2006 Bayer AG has notified Schering AG that the Executive Board and Supervisory Board of Bayer AG have decided to propose to the shareholders of Schering AG an all-cash takeover offer of EUR 86 per share. This offer represents a premium of ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 17.03.2006 Schering AG, Germany announced today that the U.S. Food and Drug Administration (FDA) has approved the new low dose, monophasic oral contraceptive YAZ(R) (3mg drospirenone/20 mcg ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 12.03.2006 Schering AG, Germany confirmed today that it has been informed by Merck KGaA representatives during the weekend that Merck KGaA intends to make an all-cash offer for the shares of ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 20.02.2006 The Executive Board of Schering AG has announced its decision to purchase own shares on the stock market up to the value of EUR 500 million over a period from March 1, 2006 to ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 20.12.2005 Schering AG (FSE: SCH, NYSE: SHR) announced today that a dividend of EUR 1.20 per share will be proposed to the Annual General Meeting on April 19, 2006 based on a continuous positive ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 28.07.2005 Schering AG announced today the disclosure data from the CONFIRM 2 trial with PTK/ZK in the second-line treatment of metastatic colorectal cancer (mCRC). This decision was based on ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 21.03.2005 Schering AG announced today that the analysis of progression free survival (PFS) as assessed by central radiology review in the CONFIRM 1 trial with the investigational drug PTK/ZK ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 20.01.2005 Schering AG (FSE: SCH, NYSE: SHR) announced today that earnings for fiscal year 2004 are expected to be well above previous estimates. On the basis of preliminary figures, the ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Berlin, July 31, 2003 - Schering AG, Germany (FSE: SCH, NYSE: SHR) announced today that net sales of the Schering AG Group were EUR2.338 billion, 8% less compared to the previous year. The ...